These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32953493)

  • 1. The impact of
    Zhao C; Jiang T; Li J; Wang Y; Su C; Chen X; Ren S; Li X; Zhou C
    Transl Lung Cancer Res; 2020 Aug; 9(4):1149-1158. PubMed ID: 32953493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Huang LT; Zhang SL; Han CB; Ma JT
    Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
    Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
    Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
    BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
    Grant MJ; Aredo JV; Starrett JH; Stockhammer P; van Alderwerelt van Rosenburgh IK; Wurtz A; Piper-Valillo AJ; Piotrowska Z; Falcon C; Yu HA; Aggarwal C; Scholes D; Patil T; Nguyen C; Phadke M; Li FY; Neal J; Lemmon MA; Walther Z; Politi K; Goldberg SB
    Clin Cancer Res; 2023 Jun; 29(11):2123-2130. PubMed ID: 36913537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characteristics and clinical outcomes of
    Su J; Zhong W; Zhang X; Huang Y; Yan H; Yang J; Dong Z; Xie Z; Zhou Q; Huang X; Lu D; Yan W; Wu YL
    Oncotarget; 2017 Dec; 8(67):111246-111257. PubMed ID: 29340050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.
    Chung KP; Wu SG; Wu JY; Yang JC; Yu CJ; Wei PF; Shih JY; Yang PC
    Clin Cancer Res; 2012 Jun; 18(12):3470-7. PubMed ID: 22510346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent
    Qin Z; Zhang H; Yan P; Yu L; Hong C; Calvetti L; Passaro A; Araujo A; Chen Y
    J Thorac Dis; 2023 Jul; 15(7):4016-4026. PubMed ID: 37559636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
    Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
    J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.
    Xu H; Li W; Yang G; Li J; Yang L; Xu F; Yang Y; Ying J; Wang Y
    Target Oncol; 2020 Jun; 15(3):357-364. PubMed ID: 32418166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Gao W; He J; Jin SD; Xu J; Yu TF; Wang W; Zhu Q; Dai H; Wu H; Liu YQ; Shu YQ; Guo RH
    Onco Targets Ther; 2019; 12():9495-9504. PubMed ID: 31819477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports.
    Meng Y; Li X; Zhang L; Ye M
    Front Oncol; 2023; 13():1129629. PubMed ID: 37795433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.